Abstract
The Oncologist 2020;25:183–185; first published on October 16, 2019; doi:10.1634/theoncologist.2019-0650 Potential conflicts of interest for the second author, Daniel F. Hayes, were missing in the original publication of this article. The article has been corrected to reflect the following financial disclosures for Dr. Hayes: Cepheid, Freenome, Inc., Artiman Ventures [Cellworks], CVS Caremark Breast Cancer Expert Panel, Agendia, Inc., EPIC Sciences, Inc., Salutogenic Innovations, Lexent, LLC (C/A); Merrimack Pharmaceuticals, Inc. [Parexel Intl. Corp.], Eli Lilly Company, Menarini/Silicon BioSystems, Veridex [Johnson & Johnson], Puma Biotechnology, Inc., Pfizer, AstraZeneca (RF); Janssen R&D, LLC [Johnson & Johnson], Menarini Silicon Biosystems, Immunicon Corporation Application No./Patent No. 05725638.0-1223-US2005008602, University of Michigan Patent Numbers US 8,790,878 B2 and US 8,951,484 B2 (IP); UpToDate, MedPage (H); Oncimmune, LLC, Inbiomotion (OI)
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
